2. UroToday Home
  3. Conference Highlights
  4. SNMMI 2024

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Reno, Nevada (UroToday.com) -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced upcoming presentations by its collaborators at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 8 to 11, 2024, in Toronto, Canada. POSLUMA® (formerly referred to as 18F-rhPSMA-7.3) is approved and indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Axumin® is approved and indicated for PET imaging in men with suspected prostate cancer recurrence based on elevated PSA levels following prior treatment.

“We are pleased that our collaborators will be sharing important scientific information about POSLUMA, Axumin and investigational experience with 18F-flotufolastat with the imaging community at SNMMI,” said David E. Gauden, D.Phil., Chief Executive Officer of Blue Earth Diagnostics. “Two presentations relate to the use of POSLUMA and 18F-flotufolastat and the effects of urinary bladder activity on imaging quality. Results from a head-to-head study to be presented by Dr. Isabel Rauscher of the Technical University of Munich examine parameters of PET imaging between 18F-flotufolastat and 68Ga-PSMA-11 in primary prostate cancer, and a presentation by Dr. Ismaheel Lawal will discuss interim results from a study at Emory assessing PET imaging quality with and without the diuretic furosemide in patients with biochemical recurrence of prostate cancer (BCR). Dr. Nadine Mallak of Oregon Health and Science University will present interim results from an ongoing study of the use of Axumin in PSMA/PET-negative BCR patients, and Dr. Rauscher will also describe clinical experience with 18F-rhPSMA-7 and 18F-flotufolastat PET in salvage therapy planning for BCR.”
Details of selected oral and poster presentations by Blue Earth Diagnostics collaborators are listed below. Presentations noted by “*” discuss results of experiences with an investigational agent for which the safety and efficacy have not been established by the FDA.

POSLUMA (flotufolastat F 18), investigational 18F-flotufolastat and 18F-rhPSMA-7
 
    
DATE:
 
Sunday, June 9, 2024
Title:
 
Impact of forced diuresis with furosemide in the evaluation of biochemical recurrence of prostate cancer with 18F-rhPSMA 7.3 PET/CT: Interim analysis of an ongoing prospective trial
Presenter:
 
Ismaheel Lawal, MD, PhD, Resident Physician, Department of Radiology and Imaging Sciences, Emory University, Atlanta Ga.
Session Title:
 
MTA05 POPs/Meet the Author: Oncology: Clinical Therapy & Diagnosis 1
Session Type:
 
Poster presentation
Session Time:
 
5:00 – 6:15 PM ET
Abstract ID.:
 
241368
 
 
 
DATE:
 
Sunday, June 9, 2024
Title:
 
*Evaluation of qualitative and quantitative PET parameters in primary prostate cancer patients: double-match comparison of 18F-flotufolastat and 68Ga-PSMA-11-PET
Presenter:
 
Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Title:
 
MTA05 POPs/Meet the Author: Oncology: Clinical Therapy & Diagnosis 1
Session Type:
 
Poster presentation
Session Time:
 
5:00 – 6:15 PM ET
Abstract ID.:
 
241424
 
 
 
DATE:
 
Saturday, June 8, 2024
Title:
 
*18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy in recurrent prostate cancer
Presenter:
 
Isabel Rauscher, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Markt Schwaben, Germany
Session Title:
 
Prostate Cancer: Focus on Imaging
Session Type:
 
Oral presentation
Session Time:
 
3:30 – 4:45 PM ET
Presentation:
 
3:35 – 3:45 PM ET
Abstract ID.:
 
241112
 
 
 
Axumin (fluciclovine F 18)
 
 
 
DATE:
 
Sunday, June 9, 2024
Title:
 
Role of 18F-fluciclovine PET/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET/CT: interim results from a prospective trial
Presenter:
 
Nadine Mallak, MD, Associate Professor, Department of Diagnostic Radiology | Molecular Imaging & Therapy, Body Imaging Director, PET/MRI, Clinical, Oregon Health and Science University, Portland, Ore.
Session Title:
 
MTA05 POPs/Meet the Author: Oncology: Clinical Therapy & Diagnosis 1
Session Type:
 
Poster presentation
Session Time:
 
5:00 – 6:15 PM ET
Abstract ID.:
 
241835


Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639. The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer. It will feature invited speakers Sean Collins, MD, PhD, Professor, Georgetown University Hospital, and Elizabeth Hawk, MD, PhD, DABNM DABR, University of California San Diego, and be moderated by Todd Cohen, MD, VP of Medical Affairs, Blue Earth Diagnostics, Inc. The symposium will be held on Sunday, June 9, 2024, from 11:15 AM – 12:15 PM ET in the Toronto Convention Center, Room 701A, South Building – 700 Level. Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research. 

Source: Blue Earth Diagnostics. (2024). Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting [Press release]. https://www.blueearthdiagnostics.com/news.